Categories Earnings, Health Care

AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot

— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.

— During the fourth quarter, the company recorded impairment charges of $155 million.

Earnings Update by AlphaStreet

— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.

— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.

— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.

— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.

— AMAG stock had retreated 24% in the past three months and 45% from this time last year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Also Read:  Earnings reports to watch for the week of Nov. 30

Most Popular

Walt Disney (DIS): After a tough FY20, the pandemic is likely to take a toll on operations next year too

The Walt Disney Company (NYSE: DIS) had a tough time in fiscal year 2020 with the COVID-19 pandemic bringing its operations to a standstill like never before. The company incurred

Earnings reports to watch for the week of Nov. 30

The recent optimism about economic recovery waned slightly this week after jobless claims increased more-than-expected to about 778,000 amid concerns over a resurgence in coronavirus cases. With the healthcare system

Yunji Inc. (YJ) Q3 2020 Earnings Call Transcript

Yunji Inc. (NASDAQ: YJ) Q3 2020 earnings call dated Nov. 26, 2020 Corporate Participants: Kaye Liu -- Investor Relations Director Shanglue Xiao -- Chairman of the Board of Directors and Chief Executive Officer Chen

Top